Literature DB >> 12932659

Small molecules that reactivate mutant p53.

V J N Bykov1, G Selivanova, K G Wiman.   

Abstract

Around half of all human tumours carry mutant p53. This allows escape from p53-induced cell cycle arrest and apoptosis. Many tumours express mutant p53 proteins at elevated levels. Restoration of wild-type p53 function should trigger massive apoptosis in tumour cells and thus eradicate tumours. Various types of small molecules have been identified that can restore native conformation and wild-type function to mutant p53. Such molecules may serve as leads for the development of novel efficient anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932659     DOI: 10.1016/s0959-8049(03)00454-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  29 in total

1.  Expression and functional characterization of platelet-derived growth factor receptor-like gene.

Authors:  Feng-Jie Guo; Wei-Jia Zhang; Ya-Lin Li; Yan Liu; Yue-Hui Li; Jian Huang; Jia-Jia Wang; Ping-Li Xie; Guan-Cheng Li
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

2.  The transduction of His-TAT-p53 fusion protein into the human osteogenic sarcoma cell line (Saos-2) and its influence on cell cycle arrest and apoptosis.

Authors:  Lei Jiang; Yushu Ma; Jinzhi Wang; Xinyi Tao; Dongzhi Wei
Journal:  Mol Biol Rep       Date:  2007-01-06       Impact factor: 2.316

3.  Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants.

Authors:  Samuel A Danziger; Jue Zeng; Ying Wang; Rainer K Brachmann; Richard H Lathrop
Journal:  Bioinformatics       Date:  2007-07-01       Impact factor: 6.937

Review 4.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

5.  Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition.

Authors:  Na Kong; Wei Tao; Xiang Ling; Junqing Wang; Yuling Xiao; Sanjun Shi; Xiaoyuan Ji; Aram Shajii; Silvia Tian Gan; Na Yoon Kim; Dan G Duda; Tian Xie; Omid C Farokhzad; Jinjun Shi
Journal:  Sci Transl Med       Date:  2019-12-18       Impact factor: 17.956

6.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

7.  Heterogeneous biomedical database integration using a hybrid strategy: a p53 cancer research database.

Authors:  Vadim Y Bichutskiy; Richard Colman; Rainer K Brachmann; Richard H Lathrop
Journal:  Cancer Inform       Date:  2007-02-20

8.  p53 Amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype.

Authors:  Anuj Kumar Sharma; Amjad Ali; Rajan Gogna; Amir Kumar Singh; Uttam Pati
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

9.  Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70.

Authors:  Laishram R Singh; Sapna Gupta; Nicholaas H Honig; Jan P Kraus; Warren D Kruger
Journal:  PLoS Genet       Date:  2010-01-08       Impact factor: 5.917

10.  Predicting positive p53 cancer rescue regions using Most Informative Positive (MIP) active learning.

Authors:  Samuel A Danziger; Roberta Baronio; Lydia Ho; Linda Hall; Kirsty Salmon; G Wesley Hatfield; Peter Kaiser; Richard H Lathrop
Journal:  PLoS Comput Biol       Date:  2008-09-04       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.